[7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome

Objective: To evaluate the outcome, safety, and patient’s tolerability of repeated intravesical onabotulinumtoxinA (BOTOX) injection for interstitial cystitis (IC)/bladder pain syndrome (PBS). Methods: The medical charts of 26 adult patients (four males and 22 females, with a mean age of 40.9 years)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Riyad Al Mousa, Yousef Alsowayan, Abdulmohsin Alfadagh, Abdulrahman Almuhrij
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2018
Materias:	Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/028c3ae9f1bf4421ad930e2c4614807e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:028c3ae9f1bf4421ad930e2c4614807e
record_format	dspace
spelling	oai:doaj.org-article:028c3ae9f1bf4421ad930e2c4614807e2021-12-02T12:36:25Z[7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome2090-598X10.1016/j.aju.2018.10.054https://doaj.org/article/028c3ae9f1bf4421ad930e2c4614807e2018-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2090598X18301487https://doaj.org/toc/2090-598XObjective: To evaluate the outcome, safety, and patient’s tolerability of repeated intravesical onabotulinumtoxinA (BOTOX) injection for interstitial cystitis (IC)/bladder pain syndrome (PBS). Methods: The medical charts of 26 adult patients (four males and 22 females, with a mean age of 40.9 years) who underwent BOTOX injections for IC/PBS from March 2010 to June 2017 were retrospectively reviewed. BOTOX injections of 100, 150 or 200 U were given depending on patient’s condition and side-effects. Preoperative and intraoperative data, and pre, same day postoperative and 4-months postoperative treatment pain scores via visual analogue scale (VAS) scoring, were collected from the files. The patient’s satisfaction rate was assessed through a short survey: ‘fully satisfied’, ‘partially satisfied’, or ‘not satisfied’, if the patient would repeat the injections, and if the patient would recommend this therapy to other patients. Results: In all, 26 charts were reviewed. Overall, the patients underwent a total of 114 procedures. Repeat procedures (at least twice) were required in 23/26 patients (88.46%), with a mean of 5.15 procedures/patient and a mean of 10.64 months between injections. The mean operative time was 7.2 min. In all, 13 patients received 200 U BOTOX, six received 100 U, and seven received 150 U. Dose adjustment was performed in 10 patients. The VAS pain score dropped to 0.62 after the procedure from 8.7 at the time of the diagnosis of IC/PBS. Five of the 26 patients had classic bladder ulcerations and three had complete resolutions of ulcers after two repeated intravesical BOTOX injections, and the remaining two had significant improvement (>50%) in their ulcers. There were no major intraoperative or postoperative complications. Postoperative urinary retention occurred in three patients, and they were managed by clean intermittent catheterisation. Another three patients had urinary tract infections but did not require admission. In all, 16 of 23 patients were fully satisfied and seven of 23 partially satisfied. About 88% of patients would repeat the treatment and 77% of them would recommend the treatment to other patients. Conclusion: Repeated intravesical BOTOX injection is an effective, well-tolerated, and safe treatment modality for patients with IC/PBS. It has very good outcomes in controlling pain symptoms and treating bladder ulcers.Riyad Al MousaYousef AlsowayanAbdulmohsin AlfadaghAbdulrahman AlmuhrijTaylor & Francis GrouparticleDiseases of the genitourinary system. UrologyRC870-923ENArab Journal of Urology, Vol 16, Iss , Pp S5- (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the genitourinary system. Urology RC870-923
spellingShingle	Diseases of the genitourinary system. Urology RC870-923 Riyad Al Mousa Yousef Alsowayan Abdulmohsin Alfadagh Abdulrahman Almuhrij [7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome
description	Objective: To evaluate the outcome, safety, and patient’s tolerability of repeated intravesical onabotulinumtoxinA (BOTOX) injection for interstitial cystitis (IC)/bladder pain syndrome (PBS). Methods: The medical charts of 26 adult patients (four males and 22 females, with a mean age of 40.9 years) who underwent BOTOX injections for IC/PBS from March 2010 to June 2017 were retrospectively reviewed. BOTOX injections of 100, 150 or 200 U were given depending on patient’s condition and side-effects. Preoperative and intraoperative data, and pre, same day postoperative and 4-months postoperative treatment pain scores via visual analogue scale (VAS) scoring, were collected from the files. The patient’s satisfaction rate was assessed through a short survey: ‘fully satisfied’, ‘partially satisfied’, or ‘not satisfied’, if the patient would repeat the injections, and if the patient would recommend this therapy to other patients. Results: In all, 26 charts were reviewed. Overall, the patients underwent a total of 114 procedures. Repeat procedures (at least twice) were required in 23/26 patients (88.46%), with a mean of 5.15 procedures/patient and a mean of 10.64 months between injections. The mean operative time was 7.2 min. In all, 13 patients received 200 U BOTOX, six received 100 U, and seven received 150 U. Dose adjustment was performed in 10 patients. The VAS pain score dropped to 0.62 after the procedure from 8.7 at the time of the diagnosis of IC/PBS. Five of the 26 patients had classic bladder ulcerations and three had complete resolutions of ulcers after two repeated intravesical BOTOX injections, and the remaining two had significant improvement (>50%) in their ulcers. There were no major intraoperative or postoperative complications. Postoperative urinary retention occurred in three patients, and they were managed by clean intermittent catheterisation. Another three patients had urinary tract infections but did not require admission. In all, 16 of 23 patients were fully satisfied and seven of 23 partially satisfied. About 88% of patients would repeat the treatment and 77% of them would recommend the treatment to other patients. Conclusion: Repeated intravesical BOTOX injection is an effective, well-tolerated, and safe treatment modality for patients with IC/PBS. It has very good outcomes in controlling pain symptoms and treating bladder ulcers.
format	article
author	Riyad Al Mousa Yousef Alsowayan Abdulmohsin Alfadagh Abdulrahman Almuhrij
author_facet	Riyad Al Mousa Yousef Alsowayan Abdulmohsin Alfadagh Abdulrahman Almuhrij
author_sort	Riyad Al Mousa
title	[7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome
title_short	[7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome
title_full	[7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome
title_fullStr	[7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome
title_full_unstemmed	[7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome
title_sort	[7] efficacy, complications and tolerability of repeated intravesical onabotulinumtoxina injections in interstitial cystitis/bladder pain syndrome
publisher	Taylor & Francis Group
publishDate	2018
url	https://doaj.org/article/028c3ae9f1bf4421ad930e2c4614807e
work_keys_str_mv	AT riyadalmousa 7efficacycomplicationsandtolerabilityofrepeatedintravesicalonabotulinumtoxinainjectionsininterstitialcystitisbladderpainsyndrome AT yousefalsowayan 7efficacycomplicationsandtolerabilityofrepeatedintravesicalonabotulinumtoxinainjectionsininterstitialcystitisbladderpainsyndrome AT abdulmohsinalfadagh 7efficacycomplicationsandtolerabilityofrepeatedintravesicalonabotulinumtoxinainjectionsininterstitialcystitisbladderpainsyndrome AT abdulrahmanalmuhrij 7efficacycomplicationsandtolerabilityofrepeatedintravesicalonabotulinumtoxinainjectionsininterstitialcystitisbladderpainsyndrome
_version_	1718393780526120960

[7] Efficacy, complications and tolerability of repeated intravesical onabotulinumtoxinA injections in interstitial cystitis/bladder pain syndrome

Ejemplares similares